Eupraxia Pharmaceuticals Statistics
Share Statistics
Eupraxia Pharmaceuticals has 35.62M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 35.62M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 366 |
| FTD / Avg. Volume | 2.17% |
Short Selling Information
The latest short interest is 128.16K, so 0.36% of the outstanding shares have been sold short.
| Short Interest | 128.16K |
| Short % of Shares Out | 0.36% |
| Short % of Float | 0.45% |
| Short Ratio (days to cover) | 27.74 |
Valuation Ratios
The PE ratio is -3.47 and the forward PE ratio is null.
| PE Ratio | -3.47 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | 6.7 |
| PB Ratio | 58.51 |
| P/FCF Ratio | -4.63 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Eupraxia Pharmaceuticals Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.78, with a Debt / Equity ratio of 4.72.
| Current Ratio | 0.78 |
| Quick Ratio | 0.78 |
| Debt / Equity | 4.72 |
| Total Debt / Capitalization | 82.51 |
| Cash Flow / Debt | -2.67 |
| Interest Coverage | -23.36 |
Financial Efficiency
Return on equity (ROE) is -16.87% and return on capital (ROIC) is -337.29%.
| Return on Equity (ROE) | -16.87% |
| Return on Assets (ROA) | -1.4% |
| Return on Capital (ROIC) | -337.29% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.29M |
| Employee Count | 29 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -89.67K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.23, so Eupraxia Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.23 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 3.17 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 46.38 |
| Average Volume (20 Days) | 16.90K |
Income Statement
| Revenue | n/a |
| Gross Profit | -209.91K |
| Operating Income | -36.90M |
| Net Income | -37.39M |
| EBITDA | -36.75M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.58 |
Balance Sheet
The company has 25.50M in cash and 10.45M in debt, giving a net cash position of 15.05M.
| Cash & Cash Equivalents | 25.50M |
| Total Debt | 10.45M |
| Net Cash | 15.05M |
| Retained Earnings | -105.50M |
| Total Assets | 10.36M |
| Working Capital | 7.52M |
Cash Flow
In the last 12 months, operating cash flow was -27.92M and capital expenditures -73.38K, giving a free cash flow of -28.02M.
| Operating Cash Flow | -27.92M |
| Capital Expenditures | -73.38K |
| Free Cash Flow | -28.02M |
| FCF Per Share | -1.16 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
EPRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -52.67% |
| FCF Yield | -26.22% |
Analyst Forecast
The average price target for EPRX is $9, which is 200% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 200% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | 1.36 |
| Piotroski F-Score | 2 |